PeptideDeepDiveSemax vs Selank: Evidence, Differences & Legal Status (2026)
Semax and Selank are often grouped together as Russian-origin cognitive peptides, but they have different structures, research histories and proposed mechanisms. This guide compares the human evidence, a direct 52-person comparison study, 2026 FDA context and current UK/EU medicine status.
Semax vs Selank: the short answer
Semax and Selank are separate heptapeptides with different research emphases. Semax is derived from ACTH(4–10) and has been studied mainly in neurological, cognitive and neuroprotective settings. Selank is derived from tuftsin and has been studied mainly in anxiety-related and neuroimmune settings.
There is some human research for both compounds, including a 2020 study that compared Semax, Selank and placebo groups in 52 healthy participants. However, that study measured resting-state brain connectivity rather than clinical benefit, and it was not a trial of Semax and Selank used together. Neither compound has a standard UK or EU marketing authorisation.
Semax vs Selank: What Is the Difference?
The clearest Semax vs Selank difference lies in the research focus. Many sources group both compounds under the label “Russian nootropic peptides.” However, each has a different structure and research history. More importantly, current evidence does not support treating either one as an approved cognitive or anxiety medicine.
| Comparison point | Semax | Selank |
|---|---|---|
| Peptide origin | Synthetic analogue of ACTH(4–10) | Synthetic analogue derived from tuftsin |
| Main research focus | Thinking, nerve protection and nerve-growth signals | Anxiety-linked pathways and immune signals |
| Proposed pathways | BDNF/TrkB and other nerve-growth signals, based largely on animal research | GABA, monoamine and immune-system signals |
| Human evidence | Several small clinical or healthy-volunteer studies, largely from Russian research groups; limited independent replication | Small Russian clinical studies and healthy-volunteer research; limited independent replication |
| UK/EU status | No standard UK or EU marketing authorisation | No standard UK or EU marketing authorisation |
How Researchers Think Semax and Selank Work
Semax: first, experimental studies link Semax to changes in brain-derived neurotrophic factor (BDNF) and TrkB signals. However, researchers carried out much of this work in animals. Therefore, those studies cannot prove a cognitive or clinical benefit in humans.
Selank: by contrast, laboratory papers and reviews discuss GABA receptors, monoamine pathways and immune signals. Researchers have also reported small human studies. Even so, the overall evidence falls far short of the large clinical programmes that Western regulators usually expect.
Semax and Selank Human Evidence: What Is Actually Available?
Both peptides have published human research, so it is too broad to describe the evidence as purely animal or laboratory based. The bigger limitation is scale, replication and generalisability. Much of the literature comes from Russian research groups, some papers are available only in Russian, and the programmes are much smaller than the clinical-development packages normally used to support UK, EU or US marketing authorisation.
For Semax, published clinical literature includes studies in neurological settings such as acute ischaemic stroke, alongside healthy-volunteer neuroimaging research. For Selank, a 2008 randomised study compared 30 patients receiving Selank with 32 receiving medazepam in people with generalised anxiety disorder or neurasthenia. These studies are relevant evidence, but they do not by themselves establish broad cognitive, anxiety or performance claims for modern online products.
Was Semax vs Selank studied directly in humans?
Yes, but the result needs careful interpretation. A 2020 study by Panikratova and colleagues assessed resting-state functional connectivity in 52 healthy participants receiving Semax, Selank or placebo. The investigators reported both shared and peptide-specific changes in connectivity involving the amygdala and temporal cortex.
This is useful because both compounds were examined within one experimental framework. However, it was a short neuroimaging study, not a clinical trial showing that one peptide is better for cognition, anxiety or any disease. It also did not test a Semax + Selank combination.
What changed with the FDA’s 2026 Semax review?
In July 2026, FDA’s Pharmacy Compounding Advisory Committee considered Semax free base and Semax acetate for possible inclusion on the 503A Bulks List. FDA evaluated nominated uses including cerebral ischaemia, migraine and trigeminal neuralgia and concluded that the available evidence was insufficient to support effectiveness for those uses. FDA also states that neither Semax form is a component of an FDA-approved drug.
FDA’s current compounding-safety page separately flags both Semax and Selank acetate for potential immunogenicity concerns related to aggregation and peptide-related impurities, while noting important gaps in human safety information. Neither the Semax PCAC review nor a compounded-drug pathway is FDA drug approval.
Are Semax and Selank Legal in the UK, Ireland, Germany and EU?
Neither compound has a standard marketing authorisation in the UK or EU. That is the clearest regulatory point. It does not automatically answer every question about possession, import, laboratory supply or exceptional clinical supply, because those issues depend on national law and how a product is presented and supplied. A “research use only” label also does not create medicine approval.
Unlicensed medicines do not have a UK marketing authorisation and may not have been assessed by the MHRA. UK law allows limited “specials” supply where an authorised medicine cannot meet an individual patient’s clinical need, but that is different from ordinary consumer sale or advertising.
Medicines placed on the Irish market generally require HPRA or EU authorisation. Ireland also has an exempt-medicinal-product route for specific patients under a prescriber’s direct responsibility when an authorised medicine is not available.
Section 21 of Germany’s Medicinal Products Act generally requires finished medicines to have national or EU marketing authorisation before they are placed on the market, subject to defined statutory exceptions.
The Netherlands also provides controlled routes for some unlicensed products, including named-patient use. Those exceptional routes are not equivalent to a normal marketing authorisation or unrestricted retail supply.
At EU level, Directive 2001/83/EC provides the general medicinal-product framework. The legal classification of a specific product can depend on its presentation, intended function and national implementation, so “unapproved” is more precise than a blanket claim that possession is universally legal or illegal across Europe.
Semax and Selank vs BPC-157 and TB-500: How They Compare
Semax vs Selank mainly compares two compounds from brain and nervous-system research. By contrast, researchers usually discuss BPC-157 and TB-500 in relation to tissue-repair models. Therefore, a comparison with those compounds crosses into a different research category.
| Peptide | Main research category | Human-evidence picture | UK/EU status |
|---|---|---|---|
| Semax | Thinking and nerve protection | Russian research, including well-known animal studies; few independent teams have repeated the findings | No standard UK or EU marketing authorisation |
| Selank | Anxiety-linked and immune signals | Small Russian human studies plus laboratory research; few independent teams have repeated the findings | No standard UK or EU marketing authorisation |
| BPC-157 legal status and human evidence | Tissue-repair models | Human evidence remains very limited | No standard UK or EU marketing authorisation |
| TB-500 legal status and evidence | Soft-tissue-repair models | Some sources mix this evidence with thymosin beta-4 research; direct human evidence remains limited | No standard UK or EU marketing authorisation |
For the broader cluster, see our evidence-led comparison of seven peptide groups. You can also read the individual Semax evidence guide en Selank evidence guide.
Overall, Semax and Selank’s Russian history creates a different evidence picture from BPC-157 and TB-500. However, that history does not create UK, Irish, German or EU approval. Likewise, calling a product a “research chemical” does not guarantee quality or settle whether its supply, import or marketing follows the law.
Frequently Asked Questions
What is the difference between Semax and Selank?
Semax is an ACTH(4–10)-derived peptide studied mainly in neurological and cognitive contexts. Selank is a tuftsin-derived peptide studied mainly in anxiety-related and neuroimmune research. Their evidence bases and proposed mechanisms are not interchangeable.
Have Semax and Selank been compared in the same human study?
Yes. A 2020 study included 52 healthy participants in separate Semax, Selank and placebo groups and assessed resting-state functional connectivity. It did not test the two peptides together and did not establish clinical efficacy.
Are Semax and Selank authorised medicines in the UK or EU?
Neither has a standard UK or EU marketing authorisation. Unlicensed-medicine, import, supply and possession rules are separate legal questions and can vary by jurisdiction.
Did FDA approve Semax after its 2026 review?
No. FDA’s July 2026 review concerned possible 503A Bulks List inclusion for Semax-related bulk drug substances. That compounding-policy process is not FDA approval of Semax as a drug.
Bronnen
- Panikratova YR et al. (2020). Functional Connectomic Approach to Studying Selank and Semax Effects — 52 healthy participants in separate Semax, Selank and placebo groups.
- Zozulia AA et al. (2008). Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurasthenia — 62-patient comparison with medazepam.
- Semax clinical literature: acute ischaemic stroke clinical study; mechanistic background: BDNF/TrkB animal research.
- U.S. Food and Drug Administration (2026). FDA briefing document for Semax-related bulk drug substances; see also FDA’s current compounding safety summary for Semax and Selank acetate.
- MHRA. Supply unlicensed medicinal products (“specials”).
- Health Products Regulatory Authority, Ireland. Exempt medicinal products.
- German Federal Ministry of Justice. Medicinal Products Act (Arzneimittelgesetz), including section 21.
- European Union. Directive 2001/83/EC, consolidated version applicable from 1 January 2025.